Maumus Marie, Pers Yves-Marie, Ruiz Maxime, Jorgensen Christian, Noël Danièle
IRMB, université de Montpellier, Inserm U1183, 80, avenue Augustin Fliche, 34295 Montpellier, France.
IRMB, université de Montpellier, Inserm U1183, 80, avenue Augustin Fliche, 34295 Montpellier, France - Unité d'immunologie clinique et de thérapeutique des maladies ostéoarticulaires, département de rhumatologie, hôpital Lapeyronie, 34000 Montpellier, France.
Med Sci (Paris). 2018 Dec;34(12):1092-1099. doi: 10.1051/medsci/2018294. Epub 2019 Jan 9.
Mesenchymal stromal or stem cells (MSCs) are multipotent adult cells that can be isolated from a variety of adult or neonatal tissues, such as bone marrow, fat tissue, placenta or umbilical cord. A therapy based on MSCs can be justified in osteoarthritis (OA) thanks to their differentiation abilities but mostly, to their paracrine and immunosuppressive properties. Possible therapeutic strategies therefore rely on the articular injection of MSCs suspensions for trophic activity or the implantation of MSCs combined with biodegradable materials for tissue engineering applications. Depending on the mode of administration and behavior after implantation, they can decrease local inflammation, prevent chondrocyte hypertrophy and apoptosis as well as differentiate into cartilage-forming chondrocytes. In this review, we summarize pathophysiological and mechanistic data and discuss perspectives confirming the interest of MSCs as a potential therapeutic strategy in OA.
间充质基质细胞或干细胞（MSCs）是多能成体细胞，可从多种成人或新生儿组织中分离出来，如骨髓、脂肪组织、胎盘或脐带。基于MSCs的治疗在骨关节炎（OA）中具有合理性，这得益于它们的分化能力，但主要是由于它们的旁分泌和免疫抑制特性。因此，可能的治疗策略依赖于关节内注射MSCs悬液以发挥营养活性，或植入与可生物降解材料结合的MSCs用于组织工程应用。根据给药方式和植入后的行为，它们可以减轻局部炎症，防止软骨细胞肥大和凋亡，并分化为形成软骨的软骨细胞。在这篇综述中，我们总结了病理生理学和机制数据，并讨论了证实MSCs作为OA潜在治疗策略的前景。
